Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden

by Rong Wang, Rong Wang, Yuchen Yang, Wei-Wu Ye, Wei-Wu Ye, Jianxing Xiang, Songan Chen, Wei-Bin Zou, Wei-Bin Zou, Xiao-Jia Wang, Xiao-Jia Wang, Tianhui Chen, Tianhui Chen, Wen-Ming Cao, Wen-Ming Cao
Published 2021-02-01